Citations

Showing 10 of 108135 citations.

Response to “Letter to the editor in response to: Associations of sleep and female sexual function: good sleep quality matters”
Kapoor, Ekta , Mara, Kristin C. , Mara, Kristin, Mara, Kristin C , Kling, Juliana M. , Faubion, Stephanie S.

Mayo Clinic

Menopause | September 21, 2021 | Volume: 28 | Issue: 11 | Pages: 1323-1324

10.1097/gme.0000000000001859 | PMID 34547002 Get It

DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer
Zou, Qi , Wang, Xiaolin , Ren, Donglin , Hu, Bang, Tang, Guannan , Zhang, Yu , Huang, Meijin , Pai, Rish K. , Win, Aung Ko , Yu, Huichuan , Luo, Yanxin , Yu, Huichuan , Luo, Yanxin , Win, Aung K , Buchanan, Daniel D. , Newcomb, Polly A. , Grady, William M.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | September 21, 2021 | Volume: 9 | Issue: 9 | Pages: e002671

10.1136/jitc-2021-002671 | PMID 34548385 Get It

Background Tumor-infiltrating lymphocytes (TILs), especially CD8+ TILs, can be used for predicting immunotherapy responsiveness and survival outcome. However, the evaluation of CD8+ TILs currently relies on histopathological methodology with high variability. We therefore aimed to develop a DNA methylation signature for CD8+ TILs (CD8+ MeTIL) that could evaluate immune response and prognosis in colorectal cancer (CRC). Methods A CD8+ MeTIL signature score was constructed by using CD8+ T cell-specific differentially methylated positions (DMPs) that were identified from Illumina EPIC methylation arrays. Immune cells, colon epithelial cells, and two CRC cohorts (n=282 and 335) were used to develop a PCR-based assay for quantitative analysis of DNA methylation at single-base resolution (QASM) to determine CD8 + MeTIL signature score. Results Three CD8+ T cell-specific DMPs were identified to construct the CD8+ MeTIL signature score, which showed a dramatic discriminability between CD8+ T cells and other cells. The QASM assay we developed for CD8+ MeTIL markers could measure CD8+ TILs distributions in a fully quantitative, accurate, and simple manner. The CD8+ MeTIL score determined by QASM assay showed a strong association with histopathology-based CD8+ TIL counts and a gene expression-based immune marker. Furthermore, the low CD8+ MeTIL score (enriched CD8+ TILs) was associated with MSI-H tumors and predicted better survival in CRC cohorts. Conclusions This study developed a quantitative DNA methylation-based signature that was reliable to evaluate CD8+ TILs and prognosis in CRC. This approach has the potential to be a tool for investigations on CD8+ TILs and a biomarker for therapeutic approaches, including immunotherapy.
Female participation in U.S. oncology clinical trials registered on ClinicalTrials.gov from 2008 to 2020.
Perera, Nirosha D. , Bell, Alexander , Stavins, MaKenna A. , Saleki, Massoud , Ionescu, Ruxandra, Wang, Max , Tao, Jacqueline J. , Sarsour, Nadeen , OʼKeefe, Ryan , Pun, Matthew , Takasugi, Jordan M., King, Roderick K., Bellomo, Tiffany R. , Litt, Henry K. , Fattahi, Sayeh , Bell, Alexander, Ionescu, Ruxandra, Shyu, Margaret , Ji, Sunjong , Steinberg, Jecca R , Mahipal, Amit , Turner, Brandon E.

Mayo Clinic

Journal of Clinical Oncology | September 21, 2021 | Volume: 39 | Issue: 28_suppl | Pages: 85-85

10.1200/jco.2020.39.28_suppl.85 Get It

85 Background: Females are thought to be underrepresented in clinical trials, which may lead to care disparities. We characterized female enrollment trends in U.S. oncology trials registered on ClinicalTrials.gov and identified features associated with accurate representation. Methods: We employed a cross-sectional study design with descriptive, logistic regression, and cox regression analyses. We downloaded 270,172 studies registered on the Aggregate Analysis of the ClinicalTrials.gov database from October 1, 2008 to March 9, 2020, excluding non-interventional and reproductive organ specific trials. We then applied cancer/oncology specific Medical Subject Heading terms and manually reviewed the remaining 27,521 trials for true oncology content. Prevalence-corrected estimates for female participation were calculated as the percentage of females among trial participants divided by the percentage of females in the disease population per U.S. Surveillance, Epidemiology, and End Results Program (SEER) data (participation to prevalence ratio [PPR]), with a range between 0.8 and 1.2 reflecting accurate female representation in the trial. Results: Of 26,894 trials meeting eligibility criteria, 9,059 trials were completed in the U.S., 2,499 trials reported completed study status, and only 1,256 trials reported sex. Among 1,256 oncology trials and 229,056 participants, overall female representation was 46.9% (95% CI, 45.4-48.4%). 43% of trials were industry funded, 29% academic, and 28% U.S. government. Females were underrepresented compared to their disease burden in anal canal (PPR 0.21), thyroid (PPR 0.57), stomach (PPR 0.68), kidney (PPR 0.77), and bone (PPR 0.79) cancer trials. They were accurately represented in head and neck (PPR 0.80), lung (PPR 0.84), bladder (PPR 0.85), skin (PPR 0.88), pancreas (PPR 0.88), colon (PPR 0.90), hematologic (PPR 0.91), liver (PPR 1.01), CNS (PPR 1.03), soft tissue (PPR 1.05), and esophagus (PPR 1.05) cancer trials. Accurate representation was significantly associated with industry funding and pancreas cancer trial focus, but not associated with trial type (medical, surgical, radiation, other invasive, other) (Table). Conclusions: Females are underrepresented compared to their disease burden in many solid tumor clinical trials. Stakeholders can look to industry funded and pancreas cancer trials as models of improvement, but must increase female representation in clinical trials to improve cancer care. [Table: see text]
Disaggregating Pacific Islanders and major Asian subpopulations to reveal hidden breast cancer disparities.
Taparra, Kekoa , Patel, Rohan, Santos, Patricia Mae G. , Dee, Edward Christopher , Dao, Dyda , Chino, Fumiko

Mayo Clinic

Journal of Clinical Oncology | September 21, 2021 | Volume: 39 | Issue: 28_suppl | Pages: 80-80

10.1200/jco.2020.39.28_suppl.80 Get It

80 Background: The Asian American, Native Hawaiian, and Other Pacific Islander (AA/NHPI) population is the fastest growing and most socioeconomically heterogeneous racial/ethnic group in the US. AA/NHPI breast cancer outcomes are often reported as superior to Non-Hispanic Whites (NHW) however evidence suggests aggregating AA/NHPI masks disparities among subpopulations. As NHPI is often ignored as one of five official US races, this study aims to disaggregate AA and NHPI to unmask breast cancer disparities. Methods: An IRB exempt, retrospective cohort study using the National Cancer Database was conducted for women diagnosed with breast cancer in 2004-2016. AA and NHPI patients were compared with the majority NHW group. AA was separated into pertinent geographical origins: East Asian (EA; Chinese, Japanese, Korean), South Asian (SA; Indian, Pakistani), and Southeast Asian (SEA; Filipino, Vietnamese, Laotian, Hmong, Cambodian). Descriptive statistics were used. Logistic and Cox proportional hazard regressions assessed adjusted Odds Ratios (aORs) and adjusted Hazards Ratios (aHR), respectively, with 95% confidence intervals (95%CI). Analyses were adjusted for patient factors (age, insurance, income, rural/urban, education, hospital region, hospital distance, Deyo comorbidity score) and cancer characteristics (grade, stage, metastases, diagnosis year, hormone status). Results: Of 2,073,822 women there were 28,311 EA, 13,259 SA, 21,645 SEA, 5,375 NHPI, and 2,005,232 NHW. The median age was 62 years with median 66 month follow-up. Compared to NHW (9.6%), presentation with late-stage disease (Stage III/IV) was higher in NHPI (12%), SA (12%), and SEA (11%), but not EA (7.5%). On adjusted analysis (Table), EA was the only group with a statistical difference from NHW with aOR=0.85 (95%CI=0.76-0.94). Kaplan-Meier test for overall survival (OS) showed differences between ethnic/racial groups with NHPI having worse OS than AA subpopulations (p<0.0001). On adjusted analysis (Table), all AA subpopulations had lower risk of death compared to NHW: EA (aHR=0.69; 95%CI=0.64-0.74), SA (aHR=0.65; 95CI=0.59-0.71), and SEA (aHR=0.78; 95%CI=0.73-0.84) however the NHPI group had a greater risk of death (aHR=1.14; 95%CI=1.02-1.28). Conclusions: NHPI women with breast cancer have worse outcomes compared to NHW. This is masked by superior AA outcomes when aggregated. The continual improper aggregation of AA with NHPI downplays NHPI cancer disparities. Proper disaggregation of NHPI from AA warrants greater attention.[Table: see text]
The economic cost and sustainability of the precision oncology promise.
Scheckel, Caleb , Orme, Jacob J. , Tella, Sri Harsha , Kommalapati, Anuhya , Khera, Nandita , Kommalapati, Anuhya , Desai, Aakash , Jensen, Chelsee , Pritchett, Joshua C. , Mahipal, Amit , Go, Ronald S.

Mayo Clinic

Journal of Clinical Oncology | September 21, 2021 | Volume: 39 | Issue: 28_suppl | Pages: 7-7

10.1200/jco.2020.39.28_suppl.7 Get It

7 Background: Despite the promise of precision oncology, the cost-effectiveness of targeted treatments is debated. Until now, the increase in price of oral targeted anti-cancer treatments used in common malignancies has not been evaluated. Here, we report patterns in price changes from 2015-2019 for multiple oral anti-cancer medications for common solid tumor malignancies. Methods: We utilized the publicly available Medicare Part D provider utilization and payment database from 2015 to 2019. We extracted drug prices (using generic names) for commonly used targeted oral anticancer agents for lung, breast, and prostate cancer. The primary outcome was the correlation of average change in Medicare spending per dosage unit among the multiple brand-name medications within each class available. We additionally calculated compound annual growth rates (CAGRs) [i.e. mean annual growth rates over a specified period of time] for medication costs within each class, and compared it with the consumer price index (a measure of the average change over time in the prices of consumer items). Results: The study included 6 EGFR inhibitors (1 generic), 5 ALK inhibitors, 2 BRAF inhibitors, 3 hormonal agents (1 generic), 3 CDK4/6 inhibitors, 2 PARP inhibitors, and 7 anti-androgen agents (2 generic). The median (range) Pearson correlation coefficient values for drugs within each class were 0.967 (0.915-0.978) for EGFRi, 0.981 (0.966-0.989) for ALKi, 0.996 for BRAFi, 0.994 (0.992-0.999) for CDK4/6i, 0.855 for PARPi, and 0.442 (-0.522-0.962) for anti-androgens. Except for anti-androgens, all other drug classes showed strong linear association in price increase between two drugs within the same-class. A coefficient could not be calculated for therapies with 2 or fewer data points ( i.e., generic erlotinib, dacomitinib, generic abiraterone, apalutamide, and darolutamide). There was no significant correlation between expenditure for anti-estrogen agents. The median (range) CAGRs in costs over this 5-year period were: were 4.56% for EGFRi, 6.40% for ALKi, 2.58% for BRAFi, 5.48% for hormonal agents, 5.21% for CDK4/6i, 27.29% for PARPi, and 34.8% for anti-androgen agents. Conclusions: The median CAGR in costs for modern oral precision driven cancer therapeutic classes mostly outpaced CPI (2.26%/year), and the average inflation rate (1.90%/year). Increase in cost within the same class should be weighed against incremental clinical benefit for the patients. For most classes despite there being multiple agents, the rise in drug expenditures correlated closely, calling into question the true value of within class competition. There is an urgent need for drug pricing reform given the average expenditure of Medicare part D, and ultimately out of pocket costs for our patients with cancer continues to trend upwards. Increased advocacy efforts are needed to ensure precision therapeutics remains an attainable and sustainable goal.
Assessing comprehensive care deficits in United States (U.S.) ovarian cancer programs to inform quality improvement initiatives.
Smeltzer, Matthew, Dawkins, Monique , Senter, Leigha , Yemelyanova, Anna , Bigg, Michelle, Bires, Jennifer , Dowdy, Sean C. , Magliocca, Anthony, Senter, Leigha , Boehmer, Leigh , Temkin, Sarah M. , Thaker, Premal H.

Mayo Clinic

Journal of Clinical Oncology | September 21, 2021 | Volume: 39 | Issue: 28_suppl | Pages: 256-256

10.1200/jco.2020.39.28_suppl.256 Get It

256 Background: Ovarian cancer is the leading cause of gynecologic cancer mortality in the US. Given the high burden of disease and complexities in the provision of quality care, a multidisciplinary team approach is critical to optimal care delivery. In 2019, the Association of Community Cancer Centers (ACCC) launched a multiphase, stakeholder-driven initiative to improve care for this patient population. Results of a national survey of cancer programs to identify the needs of patients are reported here. Methods: A 20 question survey was developed by an expert steering committee including gynecologic oncologists, pathologists, genetic counselors, a nurse navigator, and cancer center administrators. The instrument was designed to collect data about cancer programs, key ovarian cancer patient needs, and barriers to and opportunities for improving ovarian cancer care. The online survey was open for participation for 4 weeks using the Qualtrics platform and distributed via email to ACCC and Society of Gynecologic Oncology members. Results: We received 26 total responses from Comprehensive Community (26%), NCI-Designed Comprehensive (22%), Academic Comprehensive (22%), and Integrated Network (13%) Cancer Programs. Annual ovarian cancer cases ranged from 22 to 190 (median: 50.5). 85% of programs has a multidisciplinary team for ovarian cancer and 61% were part of a referral network. On average, programs has 1.5 phase II and 2 phase III clinical trials currently available for ovarian cancer (all programs had at least 1 trial available). Palliative care and comprehensive symptom management was integrated into the first appointment (15%), integrated at the time of recurrence (4%), and most frequently, available by consult (81%). We assessed genetic testing practices at each program. Aggregated across programs, 79% of patients received germline multipanel testing, 71% germline BRCA only, 50% somatic multigene, and 51% somatic BRCA only. The frequency of consultations included: genetic counseling (75%), nurse navigation (75%), social work (50%), dietetics (40%), financial counseling (25%). Genetic evaluations were typically ordered by Gynecologic Oncology (88%), genetic counseling (4%), or both (8%). When asked what topic they would choose for a quality improvement project, genetic testing and counseling was the most frequent choice (46%), followed by clinical trials enrollment and availability (23%), multidisciplinary team care (19%), education on best practices (15%), palliative care (15%), and ancillary services (15%). Conclusions: Multidisciplinary care for ovarian cancer was common across a range of cancer programs but integration of palliative care, social work, dietetics, and financial counseling could be improved. Expanding clinical trials and genetic testing and counseling were the most frequently identified opportunities to improve ovarian cancer care.
Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020.
Chiang, Ryan S. , Glover, Michael , Hui, Gavin , Wakelee, Heather A. , Desai, Aakash , Lythgoe, Mark Peter , Khaki, Ali Raza

Mayo Clinic

Journal of Clinical Oncology | September 21, 2021 | Volume: 39 | Issue: 28_suppl | Pages: 135-135

10.1200/jco.2020.39.28_suppl.135 Get It

135 Background: Black patients have a disproportionately high incidence and mortality from lung cancer. Despite the importance of clinical trials, there continue to be significant racial disparities in recruitment for pivotal registration studies. In 2016, the FDA recommended reporting racial enrollment with a minimum of 5 categories (White, Black, Asian, American Indian or Alaskan Native [AIAN] and Native Hawaiian or Pacific Islander [NHPI]). The International Committee of Medical Journal Editors also recommend reporting race and ethnicity. We evaluated race reporting and representation in registration trials for thoracic cancers. Methods: We reviewed the FDA website and identified all new drug licensing indications in thoracic malignancies (small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and mesothelioma) from 2006 to 2020. NSCLC was further classified as EGFR+, ALK+, other mutation and NOS (no driver mutation). Clinical trials cited on the licensing label for market authorization were recorded and the corresponding registration trial publication was identified. If race was unreported or underreported (defined as ≤3 groups) in the licensing study, then additional information was obtained from clinicaltrials.gov. We calculated the proportion of registration trials meeting FDA criteria and the proportion of each racial group in trials. Results: From 2006-2020, we identified 55 new licensing indications, involving 26 unique drugs; 5 approvals in SCLC, 49 approvals in NSCLC and 1 in mesothelioma. Prior to the FDA race reporting guidelines, 33% (6/18) of registration studies did not meet FDA requirements. This improved to 27% (10/37) after the guideline introduction. Overall 29,545 patients participated in thoracic registration trials; 66% White, 22% Asian, 2% Black, <1% AIAN, <1% NHPI, 1% other or multiple races and 9% unknown. Table shows race distribution by cancer subtype. Conclusions: Although improving, a substantial number of registrational clinical trials in thoracic oncology still do not report race per FDA guidance. In addition, Black individuals are disproportionately under-represented in registration trials. Greater efforts are needed for the inclusion of Black patients and other minorities in clinical trials.[Table: see text]
Identifying opportunities to improve equity in breast cancer care for uninsured Hispanic patients in underserved communities.
Botrus, Gehan , -Archambault, Natalie Ertz, Nafissi, Nellie , Gonzales, Miguel, Northfelt, Donald W. , Ertz-Archambault, Natalie , Kosiorek, Heidi , Gonzales, Miguel, Ernst, Brenda

Mayo Clinic

Journal of Clinical Oncology | September 21, 2021 | Volume: 39 | Issue: 28_suppl | Pages: 132-132

10.1200/jco.2020.39.28_suppl.132 Get It

132 Background: Enhancing equitable oncologic care is an increasingly emphasized priority. Our study aims to identify aspects of breast cancer (BC) care in which differences exist based on insurance coverage. Methods: We performed a retrospective, case control study, (from 2014-2020); 39 Hispanic ethnicity uninsured patients (UP) from underserved communities with newly diagnosed BC and 119 insured patients (IP) diagnosed at Mayo Clinic Arizona (MCA). Patients were matched 3:1 for age, stage, year of diagnosis, estrogen receptors and HER-2 status. Demographic information, clinical variables, and zip code level specific socioeconomic information were compared. Continuous variables were compared by Wilcoxon rank-sum test and categorical variables by chi-square test. All patients were treated at MCA. Results: Similar treatment patterns with radiotherapy, chemotherapy and surgery were observed between groups. Primary language was Spanish for 94% of UP and English for 97.5% of IP. The majority of UP were of Hispanic ethnicity (97.4%); IP were 83.2% non-Hispanic White, 9.2% Hispanic, 3.4% African American. Zip code level information reflected more unemployment with a median of 10.6% versus 6.9% p < 0.001, percent of high school or lower (53.0 % v 23.2 %, p < 0.001), and lower income for UP (33733.5 v 64728.0 p values < 0.001).BMI was significantly higher for UP (30.6 V 24.7, p = 0.005), with presence of more co-morbidities; diabetes (28.2% v 5.0%, p < 0.001), hypertension (35.9 % v 20.2%, p = 0.046), dyslipidemia (28.2% v 12.6%, p = 0.023), metabolic syndrome (p 23.7% v 8.5, p = 0.013), and tobacco use (17.9% v 2.5%, p < 0.001). Genetics consultation was performed for 62.2% IP versus 35.9% UP (p = 0.004), lower acceptance of nutrition consultation for UP (29.4% vs 7.4%, p = 0.024). Median time from mammogram to biopsy (25.5 days vs. 14 days, p = 0.056), and interval from diagnosis to treatment (62 days vs. 39 days) (p = 0.001) were less favorable for UP compared to IP. Conclusions: In comparing the status of UP and IP with newly diagnosed BC, we identified greater prevalence of co-morbidities and adverse social determinants of health in the former group. We identified access to genetic counseling, nutrition consultation, and timeliness of diagnostic biopsy and initiation of treatment as disparate features in the care pathway. These observations allowed development of tailored interventions to achieve greater equity in delivery of BC care at Mayo Clinic.
Accuracy of a Rapid Multiplex Polymerase Chain Reaction Plus a Chromogenic Phenotypic Test Algorithm for Detection of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Gram-Negative Bacilli in Positive Blood Culture Bottles
Ong, Sean Wei Xiang , Hon, Pei Yun, Wee, Sharon , Chia, Jonathan W. Z., Mendis, Shehara M, Izharuddin, Ezlyn, Lin, Ray Junhao, Chia, Po Ying , Sim, Rees Chin Swee, Chen, Mark , Lye, David Chien , Teng, Christine B. , Tambyah, Paul Anantharajah , Banerjee, Ritu , Patel, Robin , De, Partha Pratim, Chen, Mark I-Cheng , Chow, Angela , Patel, Robin , Kline, Susan , Yoong, Joanne , Vasoo, Shawn

Mayo Clinic

Clinical Infectious Diseases | September 21, 2021 | Volume: 74 | Issue: 10 | Pages: 1850-1854

10.1093/cid/ciab848 | PMID 34554228 Get It

Abstract We studied the performance of an algorithm combining multiplex polymerase chain reaction with phenotypic detection of extended-spectrum β-lactamases and carbapenemases directly from positive blood culture bottles in patients with gram-negative bacteremia and found good concordance with routine cultures. Such an algorithm may be a tool to improve time to optimal therapy in patients with gram-negative bacteremia.
Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients
Johnstone, Jennie , Meade, Maureen O. , Lauzier, François, Duan, Erick , Dionne, Joanna C. , Heels‐Ansdell, Diane , Thabane, Lehana , Lamarche, Daphnée , Zytaruk, Nicole , Mehta, Sangeeta , Dodek, Peter , McIntyre, Lauralyn , Karachi, Tim , Henderson, William R. , Wood, Gordon , Ovakim, Daniel , Herridge, Margaret S. , Granton, John , Wilcox, M. Elizabeth , Goffi, Alberto , Niven, Daniel J. , Lamontagne, François , D’Aragon, Frédérick , St.-Arnaud, Charles, Ball, Ian, Nagpal, Dave , Girard, Martin , Aslanian, Pierre, Charbonney, Emmanuel , Sligl, Wendy , Adhikari, Neill K. J. , Marquis, François, Archambault, Patrick , Khwaja, Kosar , Kristof, Arnold S. , Kutsogiannis, James, Paunovic, Bojan, Reeve, Brenda , Lellouche, François , Hosek, Paul, Tsang, Jennifer , Binnie, Alexandra , Trop, Sébastien, Loubani, Osama , Hall, Richard , Cirone, Robert, Reynolds, Steve, Lysecki, Paul, Golan, Eyal, Cartin‐Ceba, Rodrigo , Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Wallace, Christine, Sobhi, Gita, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Centoanti, John, Lamarche, Daphne, Laupacis, Andreas, Roberts, Robin, Brun‐Buisson, Christian , Reynolds, Steve, Willems, Sue, Sekhon, Tina , Dodek, Peter, Ayas, Najib , Agda, Maria, Alcuaz, Victoria, Ashley, Betty-Jean, Brewer, Kelsey, Palmer, Janice L. , Brown, Glen, Pavan, Mara, Greisdale, Donald, Foster, Denise , Logie, Suzie, Yip, Judy, Auld, F. C., Carney, Gayle, FLEMING, R.Y. Declan, Good, Jennifer, Manhas, Mandeep, Boyd, Karin, Dheere, Jane, Stelfox, Tom, Couillard, Philippe , Doig, Christopher J. , Booth, Joshua , Codan, Cassidy, Ruddell, Stacy, Cameron, C. Blake, Edison, Rhonda, Mina, Breanna, Berthiaume, Luc , Gaudet, Jonathan, Kutsiogiannis, Jim, Chowdhury, Raiyan, Davidow, Jon, Johnston, Curt, Johnston, Richard , Macala, Kim, Marcushamer, Sam, Markland, D., Matheson, Doug, Payton-Gay, Damian, Zygun, David, Hewer, Tayne, Thompson, Pat, Ge, Maggie, Hall, Janny, Matenchuk, Sharon, Baig, Nadia, McCoshen, Lorena, Alexandropoulos, Katrina, Bain, Sherri, Brandt, Michelle , Constable, Cathy, Douglas, K., Maharaj, Shaleen, Travers, Sabrina, Zarychanski, Ryan, Lys, Justin, Marten, Nicole, Bhairo, Audrey, Ferenes, Halyna, Kozak, Beata, Verrier, Debra, McLaughlin, Dawn-Lee, Blouw, Marcus , Smith, Heather , Gutieror, Oliver, Wingfield, Sherri Lynn, Boyle, M A, Hrabi, Debbie, MacDonald, Chantal, Bento, Karen, Davis, Megan , Dechert, William , Longo, Barbara, Mullen, Courtney, Skrzpek, Elysia, Wierenga, Laurenne, Abuzaiter, Wesam, Amorim, Lynda, Bauer, Rosemarie, Damota, Rachel, Ho, Hoang, Macdougall, Nicole, Thornewell, Mary, Tran, Lara , Visocchi, Jennifer, Hosek, Paul, Plaxton, Bill, Armstong, Catherine, Ellis, Janelle, Fisk, Kayla, Gabnouri, Melissa, Gordon, Emilie, Haegens, Rebecca, Halford, Lisa, Hillis, Brooklyn, Jesso, Rebecca, McLaren, Jennifer , McMillan, Elliot, Pelkmans, Mariska, Rekman, Matthew, Sinkovitis, Sylvia, Truong, Monica, White, Michelle C. , Bates, Noah, Bryden-Cromwell, Susan, Cameron, Colleen, Deen, A. Gamal El, DiGiovanni, Sheri, Foss, Anders, Lee, E. H. , MacGregor, Heidi, Galbraith, Esther, McArthur, Robyn, Mcgregor, J., Miller, Keith R. , Morris, Sharon, Parker, Shelley, Smith, Candice A. , Stoglow, Joanna, Tung, Jennifer , Vos, Melissa , Hand, Lori, Klotz, Lisa, Sabev, Alexandra, Savija, Nevena , Guyatt, Paige, Cosentino, Deanna, Lourenco, Diane, Misina, Julie, Berlingieri, Joseph, Skitch, Steven , Campbell, Tracy , Basheer, Hala, Bruder, Kathy, Cheng, Jane, Qureshi, Kaiser, Infantino, C. A. González, Karachi, Timothy, Alghuroba, Mashari, Khaled, Alia , Millen, Tina, Vaisler, Ryan, Biljan, Maya, Cosentino, Deane, Marriott, Brittany, Muscedere, John, Boyd, Gordon, D`Arsigny, Christine, Drover, John, Erb, Jason , Parker, Chris M., Sibley, Stephanie , Boyd, Tracy, Georgescu, Ilinca, Hunt, Miranda , Muscedere, D., Baker, Cathy, Engel, Jennifer, Fleming, Jennifer , Roderick, Lisa, Silk, Shelley, Spencer, Marcy, Tryon, Michelle, Nagpal, Dave, Ball, Ian, Sharpe, Michael D., Bentall, Tracey, Sturt-Smith, Jessica, Ellis, T.M., Muylaert, Mindy, Paczkowski, Cindy, Campbell, Eileen, Imervoski, Susie, Ovsenek, Athena, Rondinelli, Rebecca, Longfield, Teresa, Moyer, Amy, Norris, F. H., Sumpton, Janice, Teterycz, Karina, Lapinsky, Stephen E. , Munshi, Laveena, Brown, Maedean, Giacomino, Brittany, Jakab, Marnie, Kraguiljac, Alan, Shah, Sumesh, Tamberg, E., Cheng, Doret, Han, Andrew , Leung, Holly, Mantas, Ioanna, Rodrigues, Hilary, Wyllie, Andew, Carmargo, Mercedes, Richter, Beverly, Caporuscio, Rita, Falvo, Rachel Kressner, Fleming, Dimitra, Maxwell, Carmelina, Plantic, Karmen, McIntyre, Lauralyn, Pagliarello, Giuseppe, D`Egidio, Gianni, English, Shane, Hartwick, Mike, Hooper, Jonathan C., Kubelik, D., Meggison, Hilary , Patel, Rakesh , Po, Joseph, Rosenberg, Erin, Gomes, Brigette, Leclair, Lianne, Porteous, Rebecca , Reddie, Shawna, Watpool, Irene , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, Richard, Susanne, Weir, Sherry, Cardinal, Pierre , Jones, Gwynne, Microys, Sherissa, Sarti, Aimee , Seely, Andrew , Acres, Shelley, Mietitis, Sydney, Montroy, Kaitlyn, Aikens, Wendy, Dugal, Anne-Marie, Soth, Mark, Alhazanni, Waleed, Clarke, France, Copland, Mary, Hoad, Neala, Sheers, M., Takaoka, Alyson, Zytaruk, Nicole, Connolly, Christa, Davis, Denise, Gallinas, Tracy, Lee-Yoo, Jean, Lukinuk, Connie, Musielak, Leia, Pavunkovic, Nancy, Pelayo, Joy, Phillips, Kaitlyn , Pracsovics, Catherine, Raimondo, Julia, Stankus, Vida, Wright, Angela, Young, Crystal , Cirrone, Rob, Kavikondala, Kanthi, Pellerin, Axelle, Tomat, Laura, Carter, Jeff , Jani, J., Yaets, Brendan, Hodder, Jennifer, Khalid, Imrana, Lee, Julie , Salway, Kurtis D., Sandhu, Gyan, Santos, Marlene, Smith, Orla, Wang, Melissa, Dewhurst, Norman, Dowbenka, Ann, Kosinski, Ann, Parsons, Laura, Proceviat, J, Ramonas, Gitana, Yuen, Mae, Amaral, Andre , Fowler, Rob, Scales, Damon C. , Marinoff, Nicole, Pérez, Adic, Wang, Jane , Hatzifilalithis, Katrina, Iazzetta, John, Kolos, Chrys, Quinton, Ingrid, Herridge, Margaret, Archer, Jaimie, Fraser, Brooke , Geen-Smith, Cheryl, Matté, Andrea, Robles, Priscilla, Urrea, Cristian, Ascroft, Jane, Haji, Fatima , Ming, Jie , Suen, Matthew , Walid, Muhammad, Westlund, Jill M., McCredie, Victoria , Wilcox, Elizabeth , Farías, Paulina , Kosky, Barbara, Pugliese, Christina, Stenyk, Lia, Walczak, Karolina, Ae, Kyung, Kaur, Rajvinder , Lui, Jane , Mateo, Sophia, Pham, Nga, Heslegrave, Ronald J. , Panchbhaya, Zaynab, Sharman, Kim, Goel, Rakhi, Kozluk, Kim, Labelle, Julianne, Marsonia, Hina, Scott, Cecillia, Aslanian, P., Bélisle, Sylvain, Denault, André , Guimond, Jean‐Gilles, Halwagi, Antoine, Hebert, Paul L. , Kolan, Christopher, Mancebo, Jordi , Robillard, Nicholas , Benettaib, Fatna, Boumahni, Dounia, Caporuscio, Casey Bourdeau, Cantin, M, Côté-Gravel, Virginy, Ghamraoui, Ali, Lebrasseur, Martine, Courville, Lancelot Legendre, Lorio, S., Madrid, Maria Trinidad, Poitras, Nicole, Rigal, Romain, Salamé, Maya, Tran, V.K., Bacon, Katie, Boudreau, Nathalie , Carvajal, Cecilia, Gauthier, Lyne, Gendron, Julie, Jean, Karine, Laforest, Louise, Lembo, Antonietta, Lim, S. H., Pagé, France, Pelletier, L, Rodrigue, Marie-Christine, Bellemare, Jean-François, Bordeleau, Simon, Drouin, Christine, Duhaime, Benoit, Laberge, Ann, Lechance, Philippe, Deblois, Estel, Dionne, Maude, Lavoie, Lise, Michel, Isabelle, Pépin, A., Poulin, S., Anctil, Sarah, Marchand, Louis-Étienne , Roy, Robin, St-Arnaud, Charles , Quiroz, Héctor, Bérard, Dominique, Leclair, Marc-André, Bolduc, Virginie, Carbonneau, Élaine, Marchand, Joannie, Masse, Marie-Hélène , Cloutier, Sylvie , Guay, M, Morin, Line, Nicolson, J. T., Paquette, Isabelle, Théberge, France, Lamarche, Yoan , LeGuillan, Soazig, Serri, Karim , Verdant, Colin , Beaulieu, Yanick, Bellemare, Patrick, Rico, Philippe, Bernard, Françis , Giasson, Marc, Brunette, Véronique, Cavayas, Alexandros, Lévesque, Émilie, Labikova, Halina, Palacios, Julia , Langlois, Marie-Ève, Williams, Virginie, Nguyễn, Thùy Anh , Phaneuf, Valérie, Wang, Han Tin, Toupin, Francis, Ahern, Stéphane P., Laufer, Brian, Brosseau, Marc, Dul, Pauline, Harvey, Johanne, Inthanavong, Lotthida, Tassy, Danaë, Assayag, Helen, Bachand, M., Bétournay, Marysa, Daoust, Karine, Goyette, Kristine, Lessard, Ariane, Quach, Marceline, Barriault, Danny, Bellemare, David, Boivin, Anick, Breton, S., Cloutier, Ève, Daigle, Marjorie, Delisle-Thibeault, Charles, Giannakouros, Panagiota, Grenier, Stéphanie, Guilbault, Gabrielle, Léger, Caroline, Trembley, Marie-Claude, Gaudreau, Julie, Grégoire, Claire, Labbé, Véronique, Laprise-Rochette, Ariane, Ouellet, Caroline, Samson, Mélanie , Simoneau, Marie-David, Tourcotte, Virginie, Tran, Tuong-Vi, Lellouche, François, Sia, Ying Tung, Simon, Mathieu, Bouchard, Pierre-Alexandre, Lizotte, Patricia, Châteauvert, Nathalie, Grenier, T, Khwaja, Kosar, Deckelbaum, Dan, Gursahaney, Ash, Hornstein, David, Jayaraman, Dev , Razek, Tarek , Salasidis, Robert, Zanelli, Patrizia, Alam, Norine , Doerksen, Tonia, Matte, Gilbert, Robert, Marie‐France, Goldberg, Peter, Hatzakorzian, Roupen , Shahin, Jason , Qureshi, Salman, Campisi, Josie, Botan, Vasilica, Capilnean, Anissa, Corey, A. E., Gagné, Annick, Mian, J N, Normandin, Kathleen, Hall, Rick , Green, Robert, Gillis, Diana, Julien, Lisa, Magennis, Laura, Mitterer, Tamara, Arsenault, Joanna, Bruce-Payne, Kim, Gallant, Patti, Oeckler, Richard A. , Anderson, Brenda J., Liedl, Lavonne M., Meade, Laurie, Weist, Sueanne, Bartoo, Anna, Bauer, Debbie, Brickley, Vince, Bridges, S. Louis , Brunn, G.J., Eickstaedt, Jennifer E., Bergerson, Jill, Showalter, Sandy, Manley, Melissa, Taylor, Robert, Cryton, Margaret, Fowler, K. T., Krause, Katie, O`Brien, Jackie, Tow, Marianne, Ma, John, Moore, Kaitlin MS, Al‐Dawood, Abdulaziz, Tlayjeh, Haytham , Ghanem, Alaaeldien, Hassanien, Ahmad, Sharkawi, Ashraf El, Humaid, Felwa Bin, Alanizi, Hala, Alanizy, Nadyah, Bogami, Njoud Al, Muhaidib, Mohammed, Gramish, Jawaher , Alsomali, Randa, Devera, Nora, Villafranca, M.C. Muñoz, Fowler, Robert , Thabane, Lehana , Lauzier, François, Marshall, John C. , Arabi, Yaseen M. , Surette, M G , English, Shane , Rochwerg, Bram , Stelfox, Henry T. , Muscedere, John , Ball, Ian, Williamson, David R. , Friedrich, Jan O. , Kutsogiannis, Demetrios James , Zarychanski, Ryan , Taylor, Robert, Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Oczkowski, Simon J. W. , Bowdish, Dawn M. E. , Reynolds, Steve, Dodek, Peter, Ashley, Betty Jean, Palmer, Janice, Sekhon, Mypinder S. , Auld, Fiona, Fleming, R.Y.Declan, Stelfox, Tom, Parhar, Ken Kuljit S. , Cameron, Candice, Martin, Anne , Thompson, Pat, Bagshaw, Sean M. , Brandt, Michelle, Douglas, Kari, Zarychanski, Ryan, Valente, Maria, Olafson, Kendiss P. , Smith, Heather, Abuzaiter, Wesam, Hosek, Paul, Fisk, Kayla M., McLaren, Jennifer, White, Michelle, Deen, Aminah, Lee, Esther, McGregor, Julie, Miller, Keith, Morris, Sharon, Vos, Melissa, Belley‐Côté, Emilie P. , Shaikh, Sameer, Qureshi, Kaiser, Muscedere, John, D`Arsigny, Christine, Maslove, David M. , Fleming, Jennifer, Spencer, Marcy, Nagpal, Dave, Ball, Ian, Bosma, Karen J. , Alexander, Michelle, Norris, Faith, Munshi, Laveena , Grewal, Gagan , McIntyre, Lauralyn, D`Egidio, Gianni, English, Shane, Hooper, Jonathan, Kyeremanteng, Kwadwo , Neilipovitz, David , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, MacLeod, Rob , Rose, Dawn, Kim, John S. , Beinum, Amanda van , Fetzer, Susan, Clarke, France J. , Sheers, Melissa, Zytaruk, Nicole, Davis, Denise, Eaton, Catherine, Lukinuk, Connie, Wright, Angela, Khalid, Imrana, Lee, Julie, Lee, Yoon Min , Cuthbertson, Brian H. , Kaur, Navjot , Herridge, Margaret, Chen, Daniel Tzu-Hsuan , Haji, Fatima, Ming, Jie, Farias, Paulina, Kaur, Rajvinder, Pham, Tam Thi , Goel, Rakhi, Carrier, François Martin , Chassé, Michaël , Hébert, Paul, Kolan, Christophe , Boumahni, Dounia, Ghamraoui, Ali, Lebrasseur, Martine, Lorio, Stéphanie, Laforest, Louise, Lim, Sothun, Morrissette, Jennifer, Pagé, France, Dionne, Maude, Michel, Isabelle, Pépin, Alexandre, Poulin, Sandrine, Cloutier, Sylvie, Nicolson, Jessie, Paquette, Isabelle, Harvey, Johanne, Inthanavong, Lotthida, Daoust, Karine, Turgeon, Alexis F , Boivin, Anick, Breton, Sarah-Judith, Ouellet, Catherine, Grégoire, Claire, Samson, Mélanie, Lellouche, François, Khwaja, Kosar, Grushka, Jeremy Richard , Garcia, Laura, Magder, Sheldon A. , Corey, Alyssa, Mian, Jasmine, Hall, Rick, Green, Robert, Gillis, Diana, Anderson, Brenda, Brunn, Greg, Stern, Erin, Taylor, Robert, Fowler, Kim, Krause, Katie, Moore, Kaitlin , Ghanem, Alaaeldien, Hegazy, Mohamed I. , Villafranca, Marjane

Mayo Clinic

JAMA | September 21, 2021 | Volume: 326 | Issue: 11 | Pages: 1024

10.1001/jama.2021.13355 | PMID 34546300 Get It